SCHEMBL5872370

SCHEMBL5872370

[c]1ccc(CNCC2CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 6/20 0.47
HDAC6 Q9UBN7 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
LTA4H P09960 1/20 0.43
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC3 O15379 2/20 0.41
HDAC4 P56524 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC5 Q9UQL6 2/20 0.41
NPY5R Q15761 1/20 0.38
HDAC7 Q8WUI4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163891 0.91 HDAC6 (0.56) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL3972856 0.81 HDAC6 (0.55) CXCR4HDAC6LTA4HPRMT5WDR77
SCHEMBL5127860 0.81 ADRA1D (0.40) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL2934330 0.79 CXCR4 (0.69) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL16083006 0.79 CXCR4 (0.69) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL6633759 0.78 CXCR4 (0.46) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL23125077 0.76 HDAC6 (0.53) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL3637783 0.76 KMT2A (0.64) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL13573606 0.76 HDAC6 (0.49) CXCR4HDAC6MEN1KMT2ATP53
SCHEMBL5519379 0.73 CXCR4 (0.61) CXCR4HDAC6MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190134037-A1 INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN LANTHORN THOMAS HERBERT (US) 2019-05-09 US disclosed
US-7012075-B2 Cathepsin cysteine protease inhibitors MERCK & CO., INC. (US) 2006-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190134037-A1 INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN AAK1, NCK1, DAPK1 CXCR4 3421/4885HDAC6 1819/4885MEN1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.